Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Interaction between anticancer drug Cisplatin and copper chaperone Atox1 in human melanoma cells
Umeå universitet, Teknisk-naturvetenskapliga fakulteten, Kemiska institutionen. (Pernilla Wittung-Stafshede)
Umeå universitet, Medicinska fakulteten, Institutionen för kirurgisk och perioperativ vetenskap, Kirurgi. (Peter Naredi)
Umeå universitet, Teknisk-naturvetenskapliga fakulteten, Kemiska institutionen.
Kirurgi, Sahlgrenska sjukhuset, Göteborgs universitet.
Vise andre og tillknytning
2014 (engelsk)Inngår i: Protein peptide letters, ISSN 0929-8665, E-ISSN 1875-5305, Vol. 21, nr 1, s. 63-68Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Cisplatin (CisPt) is one of the most common anticancer drugs used against many severe forms of cancers. However, treatment with this drug causes many side effects and often, it results in the development of cell resistance. A majority of side effects as well as cell resistance are thought to develop due to CisPt interactions with proteins prior to reaching the nucleus and the DNA target. The copper (Cu) transport proteins Ctr1 and ATP7A/B have been implicated in cellular resistance of CisPt, possibly exporting the drug out of the cell. Recent in vitro work demonstrated that CisPt also interacts with the cytoplasmic Cu-chaperone Atox1, binding in or near the Cu-binding site, without expulsion of bound Cu. Whereas Ctr1 and ATP7B interactions with CisPt have been shown in vivo or ex vivo, there is no such information for Atox1-CisPt interactions. To address this, we developed a method to probe if CisPt interacts with Atox1 in human melanoma cells. Atox1-specific antibodies were linked to magnetic beads and used to immune-precipitate Atox1 from melanoma cells that had been pre-exposed to CisPt. Analysis of extracted Atox1 with inductively coupled plasma mass spectrometry demonstrated the presence of Pt in the protein fraction. Thus, CisPt-exposed human melanoma cells contain Atox1 molecules that bind some derivative of CisPt. This study gives the first indication for the intracellular presence of Atox1-CisPt complexes ex vivo.

sted, utgiver, år, opplag, sider
2014. Vol. 21, nr 1, s. 63-68
Emneord [en]
Copper-chaperone, Cisplatin, Atox1, anticancer, resistance
HSV kategori
Forskningsprogram
biologisk kemi
Identifikatorer
URN: urn:nbn:se:umu:diva-80714DOI: 10.2174/09298665113209990036ISI: 000329022400011Scopus ID: 2-s2.0-84891468313OAI: oai:DiVA.org:umu-80714DiVA, id: diva2:651190
Tilgjengelig fra: 2013-09-24 Laget: 2013-09-24 Sist oppdatert: 2023-03-23bibliografisk kontrollert
Inngår i avhandling
1. Copper-transporting proteins and their interactions with platinum-based anticancer substances
Åpne denne publikasjonen i ny fane eller vindu >>Copper-transporting proteins and their interactions with platinum-based anticancer substances
2013 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

  Cisplatin (CisPt) is an important drug that is used against various cancers, including testicular, ovarian, lung, head, and neck cancer. However, its effects are limited by cellular resistance. The resistance is believed to be multifactorial, and may be mediated to varying degree by multiple systems in cells, one of the proposed systems being the copper (Cu) transporting system. The Cu-importer Ctr1 has proven importance for cellular sensitivity to CisPt by regulating its influx, while the Golgi-localized Cu-ATP:ases ATP7A/B can putatively mediate CisPt efflux and/or drug sequestration. Atox1 is a small Cu-chaperone that normally transfers Cu between Ctr1 and ATP7A/B, prior to delivery of Cu to the proteins in the secretory pathway. Since Ctr1 and ATP7A/B are reportedly involved in CisPt-resistance, CisPt interaction with Atox1 was the focus of the project this thesis is based upon.

  Using a variety of techniques, Atox1 was found to bind CisPt, also simultaneously with Cu. The Atox1-CisPt complexes were further probed using selected mutants in studies demonstrating that only the two cysteines (Cys12 and Cys15) in the Cu-binding site of Atox1 are essential for CisPt interactions. A proposed Atox1 di-metal complex containing both Cu and CisPt was found to be monomeric, and no loss of Cu was observed. In vitro experiments demonstrated that CisPt could also bind to metal-binding domain 4 of ATP7B (WD4), and that the drug could be transferred from Atox1 to the domain. These findings indicated that Atox1 may transfer CisPt to ATP7A/B in vivo, utilizing the same transport pathway as Cu. However, the CisPt-bound Atox1 complexes were not stable over time; upon incubation, protein unfolding and aggregation were observed. Thus, in vivo, Atox1 might alternatively be a dead-end sink for CisPt.

  The effects of the ligands around the Pt-center of Pt-based anticancer drugs and drug derivatives on Atox1 binding and unfolding were also investigated. The ligands’ chemistry and geometry were shown to dictate the extent and rate of the Pt-based substances interactions with Atox1. Finally, the occurrence of Atox1-CisPt interactions in a biological environment was demonstrated by developing and applying an antibody-based method allowing analysis of metals associated with Atox1 extracted from CisPt-treated cells.

  The findings presented in this thesis show that CisPt binds to Atox1 and WD4, also simultaneously with Cu, in vitro. The results support the hypothesis that Cu-transporting proteins can mediate cellular resistance to CisPt in vivo, and provide a deeper chemical understanding of the interactions between the proteins and the drug.

sted, utgiver, år, opplag, sider
Umeå: Umeå Universitet, 2013. s. 96
Emneord
Cisplatin, Atox1, copper transport, anticancer drug, resistance, platinum, spectroscopy.
HSV kategori
Forskningsprogram
biologisk kemi
Identifikatorer
urn:nbn:se:umu:diva-80717 (URN)978-91-7459-705-9 (ISBN)
Disputas
2013-10-18, KBC-huset, KB3B1, Umeå universitet, Umeå, 09:00 (engelsk)
Opponent
Veileder
Tilgjengelig fra: 2013-09-27 Laget: 2013-09-24 Sist oppdatert: 2018-06-08bibliografisk kontrollert

Open Access i DiVA

Interaction between anticancer drug cisplatin and copper chaperone Atox1 in human melanoma cells(379 kB)509 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 379 kBChecksum SHA-512
eba6c5def5fedf1568450d4b12c128d05ce7cba36c2984014040cf4b5240ffa2a735d53dd14f23914aa3599cc62a3de0e0faa4738223ada8b3c61321c50c75b8
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstScopus

Person

Palm-Espling, MariaLundin, ChristinaBjörn, ErikNaredi, PeterWittung-Stafshede, Pernilla

Søk i DiVA

Av forfatter/redaktør
Palm-Espling, MariaLundin, ChristinaBjörn, ErikNaredi, PeterWittung-Stafshede, Pernilla
Av organisasjonen
I samme tidsskrift
Protein peptide letters

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 509 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 1232 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf